Tempest Therapeutics, Inc.

NASDAQ (USD): Tempest Therapeutics, Inc. (TPST)

Last Price

0.919

Today's Change

-0.004 (0.43%)

Day's Change

0.895 - 0.935

Trading Volume

811,466

Overview

Market Cap

40 Million

Shares Outstanding

43 Million

Avg Volume

3,136,634

Avg Price (50 Days)

0.90

Avg Price (200 Days)

1.94

PE Ratio

-0.60

EPS

-1.53

Earnings Announcement

17-Mar-2025

Previous Close

0.92

Open

0.94

Day's Range

0.895 - 0.935

Year Range

0.699 - 6.0

Trading Volume

811,466

Price Change Highlight

1 Day Change

-0.39%

5 Day Change

-6.23%

1 Month Change

14.86%

3 Month Change

-14.12%

6 Month Change

-58.79%

Ytd Change

7.05%

1 Year Change

-78.38%

3 Year Change

-77.64%

5 Year Change

-99.25%

10 Year Change

-99.99%

Max Change

-99.95%

News and Blogs
Latest Hottest Following

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Tempest Therapeutics Inc., a clinical-stage oncology company, engages in developing small molecule therapeutics to treat cancer. The company's two clinical programs are TPST-1495, a dual antagonist of EP2 and EP4, receptors of prostaglandin E2, and is currently in a Phase 1 trial in solid tumors; and TPST-1120, a selective antagonist of peroxisome proliferator-activated receptor alpha that is in a Phase 1 trial in solid tumors. It also develops TREX-1, a key cellular enzyme that regulates the innate immune response in tumors. The company was founded in 2011 and is headquartered in South San Francisco, California. Tempest Therapeutics Inc. was formerly a subsidiary of Inception Sciences, Inc.

Discussions
Be the first to like this. Showing 0 of 0 comments
Post a Comment